A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.

Rozebalamin, an ultra-high dose vitamin B12 treatment, was approved in Japan to slow disease progression in people with ALS.

Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and over 300 related neuromuscular conditions.

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...

People with ALS can benefit from voice-generating artificial intelligence, improving their quality of life, columnist Kristin Neva writes.

NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...